A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms

Journal of Affective Disorders

Volumn 72, Issue 1, 2002, Pages 85-90

  Dean, Angela J ^a,f   Bell, James ^b   Mascord, David J ^c   Parker, Gordon ^d   Christie, Macdonald J ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b The Langton Centre   (Australia)

^c University of Sydney   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Centre for Drug and Alcohol Studies   (Australia)

Author keywords

Benzodiazepines; Clinical trial; Depression; Fluoxetine; Methadone; Opiate

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; FLUOXETINE; METHADONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LIFE; MALE; METHADONE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOCIAL STATUS; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; MALE; METHADONE; NARCOTICS; PATIENT COMPLIANCE; SUBSTANCE-RELATED DISORDERS;

EID: 0036775966     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(01)00419-0     Document Type: Article

References (33)

1. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br. J. Addict. 82:1987;665-671.
2. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4:1961;561-571.
3. Bertschy G., Eap C.B., Powell K., Baumann P. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther. Drug Monit. 18:1996;570-572.
4. Brooner R.K., King V.L., Kidorf M., Schmidt C.W., Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch. Gen. Psychiatry. 54:1997;71-80.
5. Brown W.A. The placebo effect. Sci. Am. 258:(1):1998;68-73.
6. Caplehorn J.R.M., Bell J. Methadone dosage and retention of patients in maintenance treatment. Med. J. Aust. 154:1991;195-199.
7. Crawford V. Comorbidity of substance misuse and psychiatric disorders. Curr. Opin. Psychiatry. 9:1996;231-234.
8. Darke S., Hall W., Wodak A., Heather N., Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the opiate treatment index. Br. J. Addict. 87:1992;733-742.
9. Darke S., Swift W., Hall W., Ross J. Drug use, HIV risk-taking behaviour and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend. 34:1993;67-70.
10. Darke S., Ross J. The use of antidepressants among injecting drug users in Sydney, Australia. Addiction. 95:2000;407-417.
11. Greenberg R.P., Bornstein R.F., Zborowski M.J., Fisher S., Greenberg M.A. A meta-analysis of fluoxetine outcome in the treatment of depression. J. Nerv. Ment. Dis. 182:1994;547-551.
12. Iribarne C., Picart D., Dreano Y., Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam. Clin. Pharmacol. 12:1998;194-199.
13. Kleber H.D., Weissman M.M., Rounsaville B.J., Wilber C.H., Prusoff B.A., Riordan C.E. Imipramine as treatment for depression in addicts. Arch. Gen. Psychiatry. 40:1983;649-653.
14. Kranzler H.R., Kadden R.M., Burleson J.A., Babor T.F., Apter A., Rounsaville B.J. Validity of psychiatric diagnoses in patients with substance use disorders: is the interview more important than the interviewer? Comp. Psychiatry. 36:1995;278-288.
15. Lader M. Anxiety or depression during withdrawal of hypnotic treatments. J. Psychosom. Res. 38:(Suppl. 1):1994;113-123.
16. Madden C., Ong B., Singer G. Mood state of heroin-dependent persons undergoing methadone detoxification. Int. J. Addict. 22:1987;93-102.
17. Mattocks K.M., Horwitz R.I. Placebos, active control groups, and the unpredictability paradox. Biol. Psychiatry. 47:2000;693-698.
18. Miller C.A., Hooper C.L., Bakish D. A comparison of placebo response with major depressive disorder in patients recruited through newspaper advertising versus consultation referrals. Psychopharm. Bull. 33:1997;647-651.
19. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
20. Nunes E.V., Quitkin F.M., Donovan S.J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P.J., Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. Arch. Gen. Psychiatry. 55:1998;153-160.
21. Olfson M., Marcus S.C., Pincus H.A., Zito J.M., Thompson J.W., Zarin D.A. Antidepressant prescribing practices of out-patient psychiatrists. Arch. Gen. Psychiatry. 55:1998;310-316.
22. Parker G., Hadzi-Pavlovic D., Sengoz A., Boyce P., Mitchell P., Wilhelm K., Hickie I., Brodaty H. A brief self report depression measure assessing mood state and social impairment. J. Affect. Disord. 30:1994;133-142.
23. Petrakis I., Carroll K., Nich C., Gordon L., Kosten T., Rounsaville B. Fluoxetine treatment of depressive disorders in methadone maintained opioid addicts. Drug Alcohol Depend. 50:1998;221-226.
24. Preston K.L., Umbricht A., Epstein D.H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch. Gen. Psychiatry. 57:2000;395-404.
25. Rabkin J.G., Stewart J.W., McGrath P.J., Markowitz J.S., Harrison W., Quitkin F.M. Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatr. Res. 21:1987;9-22.
26. Roszell D.K., Calsyn D.A. Personality and demographic characteristics associated with the prescribing of psychoactive medications for methadone maintenance patients. Int. J. Addict. 21:1986;175-190.
27. Rounsaville B.J., Weissman M.M., Crits-Christoph K., Wilber C., Kleber H. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch. Gen. Psychiatry. 39:1982;151-156.
28. Rounsaville B.J., Kosten T.R., Weissman M.M., Kleber H.D. Prognostic significance of psychopathology in treated opiate addicts, a 2.5-year follow-up study. Arch. Gen. Psychiatry. 43:1986;739-745.
29. Smith B.D., Salzman C. Do benzodiazepines cause depression? Hosp. Commun. Psychiatry. 42:1991;1101-1102.
30. Titievsky J., Seco G., Barranco M., Kyle E.M. Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double blind study. J. Clin. Psychiatry. 43:1982;454-456.
31. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey Manual and Interpretation Guide. 1993;New England Medical Centre, The Health Institute, Boston, MA.
32. White K., Knado J., Park T., Waternaux C., Brown W.A. Side effects and the 'blindability' of clinical drug trials. Am. J. Psychiatry. 149:1992;1730-1731.
33. Woody G.E., O'Brien C.P., Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am. J. Psychiatry. 132:1975;447-450.